BCAL Diagnostics Limited (ASX:BDX)

BCAL Diagnostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	2.62	3.1	2.85	0.72	0.28	0.44
Revenue Growth (YoY)	-29.28%	8.60%	296.94%	161.09%	-37.74%	71.19%
Gross Profit	2.62	3.1	2.85	0.72	0.28	0.44
Selling, General & Admin	3.94	3.61	2.76	1.46	0.37	0.52
Research & Development	4.44	4.36	4.47	1.91	0.66	0.47
Operating Expenses	10.24	9.13	7.58	3.77	1.21	1.14
Operating Income	-7.62	-6.03	-4.73	-3.05	-0.93	-0.7
Interest Expense	-0.1	-0.1	-0.02	-	-	-
Other Non Operating Income (Expenses)	-0.28	-0.27	-0.32	-0.34	-0.59	-
Pretax Income	-7.99	-6.4	-5.06	-3.39	-1.52	-0.7
Net Income	-7.99	-6.4	-5.06	-3.39	-1.52	-0.7
Net Income to Common	-7.99	-6.4	-5.06	-3.39	-1.52	-0.7
Shares Outstanding (Basic)	314	246	211	204	135	115
Shares Outstanding (Diluted)	314	246	211	204	135	115
Shares Change (YoY)	42.07%	16.75%	3.24%	51.65%	17.28%	12.23%
EPS (Basic)	-0.03	-0.03	-0.02	-0.02	-0.01	-0.01
EPS (Diluted)	-0.03	-0.03	-0.02	-0.02	-0.01	-0.01
Free Cash Flow	-8.07	-5.67	-6.41	-3.25	-1.21	-0.67
Free Cash Flow Per Share	-0.03	-0.02	-0.03	-0.02	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-290.48%	-194.54%	-165.64%	-424.13%	-339.30%	-157.51%
Profit Margin	-304.89%	-206.58%	-177.44%	-471.08%	-554.03%	-157.51%
Free Cash Flow Margin	-307.90%	-183.15%	-224.72%	-451.54%	-439.70%	-150.52%
EBITDA	-6.91	-5.67	-4.67	-3.03	-0.93	-0.69
EBITDA Margin	-263.53%	-182.91%	-163.58%	-	-	-155.76%
D&A For EBITDA	0.71	0.36	0.06	0.02	0.01	0.01
EBIT	-7.62	-6.03	-4.73	-3.05	-0.93	-0.7
EBIT Margin	-290.48%	-194.54%	-165.64%	-	-	-157.51%

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.